NanoViricides Seeks Rare Pediatric Disease Designation for Measles Treatment Candidate

NanoViricides, Inc., a clinical-stage company developing broad-spectrum antivirals, has filed an application with the U.S. Food and Drug Administration for Rare Pediatric Disease Drug designation for NV-387 as a treatment for measles. This filing follows a previously submitted orphan drug designation application and could make the company eligible for a Priority Review Voucher upon approval, supporting regulatory advancement of NV-387 as a potential treatment in a market where no approved measles therapies currently exist. The company's lead drug candidate is NV-387, a broad-spectrum antiviral drug that the company plans to develop as a treatment for RSV, COVID, Long COVID, influenza, and other respiratory viral infections. According to company information, NV-387 is a unique broad-spectrum antiviral that is also effective in animal models for monkeypox, smallpox, and measles.

The company's other advanced drug candidate is NV-HHV-1 for the treatment of all herpesvirus infections including HSV-1 cold sores, HSV-2 genital ulcers, VZV shingles, and chickenpox. The company notes it cannot project an exact date for filing an Investigational New Drug application for any of its drugs because of dependence on a number of external collaborators and consultants. NV-387 has successfully completed a Phase I human clinical trial in healthy volunteers with no reported adverse events, and the company is currently focused on advancing NV-387 into Phase II human clinical trials. The latest news and updates relating to NanoViricides are available in the company's newsroom at https://ibn.fm/NNVC.

The Rare Pediatric Disease designation program is designed to encourage development of new drugs and biologics for the prevention and treatment of rare pediatric diseases. If granted, this designation could provide NanoViricides with important regulatory benefits and potential market exclusivity. The measles virus remains a significant global health concern despite the availability of vaccines, with outbreaks continuing to occur in various regions. The absence of approved therapeutic treatments for measles creates a substantial unmet medical need, particularly for vulnerable pediatric populations who may experience severe complications from the disease.

Measles can lead to serious complications including pneumonia, encephalitis, and death, particularly in young children and immunocompromised individuals. The development of an effective therapeutic treatment could complement vaccination efforts and provide an important tool for managing outbreaks and treating severe cases. NanoViricides' approach involves creating special purpose nanomaterials for antiviral therapy, with NV-387 representing their most advanced candidate across multiple viral indications. The company's progress with NV-387 reflects ongoing research efforts to address viral diseases through novel therapeutic approaches beyond traditional vaccine development.